Romain Corre
Rouen, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 22, 2026
Summary of second-line treatment of stage IV NSCLC without oncogenic addiction
Journal: Bulletin du cancer
Published: July 19, 2025
Real-life first-line systemic treatments for metastatic non-small cell lung cancer (mNSCLC) - Data from the KBP-2020-CPHG cohort
Journal: Bulletin du cancer
Published: July 07, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Journal: Nature medicine
Published: April 01, 2025
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).
Journal: Clinical lung cancer
Published: November 17, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Journal: The Lancet. Respiratory medicine
Published: May 16, 2024
Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.
Journal: Clinical lung cancer
Published: February 04, 2024
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Journal: Targeted oncology
Published: October 21, 2023
Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
Journal: PloS one
Published: May 19, 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 07, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.
Journal: Journal of geriatric oncology
Published: November 22, 2022
Last Updated: 09/26/2026